Economic Evaluation of Treatment of Macular Edema Due to Central or Hemiretinal Vein Occlusion in the SCORE 2 Trial

May-21

Conference Paper

Authors:

Secondary:
Association for Research in Vision and Ophthalmology Annual Meeting

Location:
Denver, Colorado

URL:
https://www2.emmes.com/publications/3107https://www.arvo.org/annual-meeting/meeting-info/past-annual-meetings/

Keywords:
POSTER PRESENTATION; SCORE2

Abstract:
<p>SCORE2 demonstrated that, for visual acuity letter score (VALS) change, bevacizumab is non-inferior to aflibercept for treatment of macular edema due to central (CRVO) or hemi-retinal vein occlusion (HRVO).<br /> While bevacizumab was non-inferior, aflibercept had a numerical advantage in VALS letters gained.<br /> The average cost for aflibercept is 10 times that of bevacizumab, but it is not known whether the increased VALS gained offsets this cost.</p>